The formulation of Halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: Physical stability and absolute bioavailability assessment

International Journal of Pharmaceutics

Volumn 205, Issue 1-2, 2000, Pages 65-78

  Khoo, Shui Mei ^a   Porter, Christopher J H ^a   Charman, William N ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Amorphous drug; Halofantrine; Microemulsions; Solid dispersions

Indexed keywords

DEBUTYLHALOFANTRINE; DRUG CARRIER; GELUCIRE; HALOFANTRINE; INTRALIPID; MACROGOL 6000; N,N DIMETHYLFORMAMIDE; TOCOFERSOLAN; TRIACETIN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DOG; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; ENTHALPY; MALARIA; MICROEMULSION; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE; X RAY POWDER DIFFRACTION;

ANTIMALARIALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EXCIPIENTS; GELS; PHENANTHRENES; POLYETHYLENE GLYCOLS; SOLUBILITY; SUPPORT, NON-U.S. GOV'T; VITAMIN E;

EID: 0034665061     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(00)00485-3     Document Type: Article

References (17)

1. Bryson H.M., Goa K.L. Halofantrine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic potential. Drugs. 43:1992;236-258.
2. Chiou W.L., Riegelman S. Oral absorption of griseofulvin in dogs: Increased absorption via solid dispersion in polyethylene glycol 6000. J. Pharm. Sci. 59:1970;937-941.
3. Chiou W.L., Riegelman S. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 60:1971;1281-1302.
4. Elliott P.N., Ford J.L., Chan K.K. The effect of incorporation of indomethacin with polyethylene glycol 6000 in a solid dispersion on its in vivo properties in the rat. Agents Action. 15:1984;367-370.
5. Ford J.L. The current status of solid dispersions. Pharm. Acta Helv. 61:1986;69-88.
6. Ford J.L., Timmins P. The use of thermal analysis in the study of solid dispersions. Ford J.L., Timmins P. Pharmaceutical Thermal Analysis: Techniques and Applications. 1989;150-179 Ellis Horwood, Chichester, UK.
7. Hancock B.C., Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86:1997;1-12.
8. Hancock B.C., Shamblin S.L., Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res. 12:1995;799-806.
9. Humberstone A.J., Currie G.J., Porter C.J.H., Scanlon M.J., Charman W.N. A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions. J. Pharm. Biomed. Anal. 13:1995;265-272.
10. Humberstone A.J., Porter C.J.H., Charman W.N. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J. Pharm. Sci. 85:1996;525-529.
11. Jackowicz R., Nürnberg E., Hoppe R. Solid dispersions of oxazepam. Int. J. Pharm. 99:1993;321-325.
12. Karbwang J., Na Bangchang K. Clinical pharmacokinetics of Halofantrine. Clin. Pharmacokinet. 27:1994;104-119.
13. Khoo S.M., Humberstone A.J., Porter C.J.H., Edwards G.A., Charman W.N. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. Int. J. Pharm. 167:1998;155-164.
14. Serajuddin A.T.M. Solid dispersions of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 88:1999;1058-1066.
15. US Pharmacopeia XXIII, 1995. US Pharmacopeial Convention, Rockville, MD, pp. 1792.
16. ter Kuile F.O., Dolan G., Nosten F., Edstein M.D., Luxemburger C., Phaipun L., Chongsuphajaisiddhi T., Webster H.K., White N.J. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet. 341:1993;1044-1049.
17. Yoshioka M., Hancock B.C., Zografi G. Inhibition of indomethacin crystallization in poly(vinylpyrrolidone) coprecipitates. J. Pharm. Sci. 84:1995;983-986.